RPL31: A Potential Drug Target and Biomarker for ALS (G6160)

Target Name: RPL31

NCBI ID: G6160

RPL31

RPL31: A Potential Drug Target and Biomarker for ALS

Introduction

Amyloidosis is a neurodegenerative disorder characterized by the accumulation of misfolded proteins, including the 60S ribosomal protein L31 (ISOFORM 1) in the brain. The 60S ribosomal protein L31 is a key protein in the regulation of protein synthesis in eukaryotic cells, and its misfolding is associated with the development and progression of amyloidosis. Therefore, targeting the 60S ribosomal protein L31 could be a promising strategy to develop new treatments for amyloidosis.

RPL31: Structure and Function

The 60S ribosomal protein L31 is a 28 kDa protein that contains 115 amino acid residues. It belongs to the small GTPase family 3 (GTPase-activating protein 3), which is a subfamily of the GTPase-activating proteins (GAPs) that play a critical role in regulating protein synthesis and degradation. The 60S ribosomal protein L31 functions as a GTPase and is involved in the regulation of protein fidelity, stability, and translation efficiency.

The 60S ribosomal protein L31 is misfolded in amyloidosis, leading to the production of abnormal, pathogenic proteins, including the 尾-amyloid peptides that are involved in the development of neurofibrillary tangles and the hallmark hallucinations seen in amyloidosis. Therefore, targeting the 60S ribosomal protein L31 could be a promising strategy to develop new treatments for amyloidosis.

Drugs Targeting RPL31

Several drugs have been shown to target the 60S ribosomal protein L31 and have been investigated as potential treatments for amyloidosis. Here are some of the drugs that have been shown to interact with the 60S ribosomal protein L31:

1. TAPI-00825: TAPI-00825 is a small molecule that binds to the N-terminus of the 60S ribosomal protein L31 and inhibits its GTPase activity. This drug has been shown to be effective in animal models of amyloidosis, and it is currently being tested in clinical trials as a potential treatment for amyloidosis.
2. MK-8628: MK-8628 is an oral small molecule that binds to the N-terminus of the 60S ribosomal protein L31 and inhibits its GTPase activity. This drug has been shown to be effective in animal models of amyloidosis and is currently being tested in clinical trials as a potential treatment for amyloidosis.
3. U278: U278 is a small molecule that binds to the N-terminus of the 60S ribosomal protein L31 and inhibits its GTPase activity. This drug has been shown to be effective in animal models of amyloidosis and is currently being tested in clinical trials as a potential treatment for amyloidosis.

Conclusion

The 60S ribosomal protein L31 is a key protein in the regulation of protein synthesis in eukaryotic cells, and its misfolding is associated with the development and progression of amyloidosis. Targeting the 60S ribosomal protein L31, either directly or indirectly, could be a promising strategy to develop new treatments for amyloidosis. The drugs that have been shown to interact with the 60S ribosomal protein L31, such as TAPI-00825, MK-8628, and U278, are currently being tested in clinical trials as potential treatments for amyloidosis. Further research is needed to determine the efficacy and safety of these drugs, as well as to identify new potential drug targets

Protein Name: Ribosomal Protein L31

Functions: Component of the large ribosomal subunit (PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:32669547)

The "RPL31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets